Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. To avoid confusion, the Company now refers to this product as CLBS16. CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina.
Press Releases
Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020
August 6, 2020
Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020 BASKING RIDGE, N.J. (August 6, 2020) – Caladrius Biosciences, Inc. […]
Read MoreCaladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer
August 5, 2020
Caladrius Biosciences Announces the Resignation of Joseph Talamo, Chief Financial Officer BASKING RIDGE, N.J. (August 5, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors
July 28, 2020
Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors BASKING RIDGE, N.J. (July 28, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the […]
Read MoreCaladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase
June 2, 2020
Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase BASKING RIDGE, N.J. (June 2, 2020) – […]
Read MoreCaladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
May 28, 2020
Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (May 28, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
May 26, 2020
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (May 26, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […]
Read MoreCaladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
May 14, 2020
Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions Single administration of CLBS16 durably improves heart function and […]
Read MoreCaladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results
May 7, 2020
Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and […]
Read MoreCaladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
May 6, 2020
Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions BASKING RIDGE, N.J. (May 6, 2020) – Caladrius […]
Read MoreCaladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020
April 30, 2020
Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020 BASKING RIDGE, N.J. (April 30, 2020) – Caladrius Biosciences, Inc. […]
Read MoreCaladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
April 27, 2020
Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (April 27, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” […]
Read MoreCaladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
April 23, 2020
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules BASKING RIDGE, N.J. (April 23, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or […]
Read MoreCaladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage
April 23, 2020
Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage FDA authorizes new IND for the study of CLBS119 in […]
Read MoreCaladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
April 22, 2020
Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program BASKING RIDGE, N.J. (April 22, 2020) – Caladrius […]
Read MoreCaladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 5, 2020
CLBS16 ESCaPE-CMD data presented at American Heart Association 2019 Scientific Sessions demonstrated highly statistically significant improvement in coronary flow reserve and angina symptoms CLBS12 registration eligible […]
Read MoreCaladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 at 4:30 p.m. Eastern Time
February 27, 2020
BASKING RIDGE, N.J. (February 27, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at Upcoming February Conferences
February 3, 2020
BASKING RIDGE, N.J. (February 3, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at Upcoming January Conferences
January 7, 2020
BASKING RIDGE, N.J. (January 7, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences to Participate at Upcoming December Conferences
December 2, 2019
BASKING RIDGE, N.J. (December 2, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies […]
Read MoreCaladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
November 16, 2019
Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events CLBS16 cell therapy shows promise as a significant advancement in treatment […]
Read More